SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

HSBCs bearish view on CoreWeave has amplified concerns about its debt-heavy data-center expansion, rising financing costs, and potentially slowing AI demand. Traders are split between buying the selloff and anticipating a short squeeze, and warning that credit and insider-selling risks could prolong the decline.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on Middle East supply concerns, including reported tanker and energy-infrastructure attacks, while traders also weigh Ukrainian strikes on Russian oil assets. The community is split between expecting supply risks to keep oil elevated and betting that diplomacy, supply relief, or an overextended rally will bring a pullback.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A European Medicines Agency committee recommendation for Lillys Foundayo obesity pill is fueling a breakout to fresh highs, with traders also focused on the upcoming earnings report. Bulls see the pill as expanding Lillys obesity-market reach, while skeptics question whether the gains will hold and point to competition from Novo Nordisk.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being tied by traders to weakening confidence in Trump and the approaching midterms, alongside concerns about the companys limited business fundamentals and Truth Social. The discussion is broadly bearish, though some traders view the decline as a possible short-term trading bounce.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapport Therapeutics is drawing attention after RAP-219 met the primary and secondary endpoints in a Phase 2 trial for acute bipolar mania. Traders are divided: bulls view the results as proof of concept and note plans for Phase 3, while skeptics question the modest efficacy and point to agitation and discontinuation concerns as the initial rally faded.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp neocloud and AI-infrastructure selloff as traders weigh Gartners warning about the sectors economics and broader concerns over debt, funding, and project execution. The community is split between expecting further declines and buying an oversold dip; some cite the CEOs assurances about data-center financing, while others point to Horizon 2 delays and weak price action.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 results and outlook are drawing attention, with traders focusing on strong revenue growth, AI-related demand, and recurring royalties from its Vertical Power Delivery licensing business. The reaction is broadly bullish after the shares rise, though some traders question the valuation and weigh the earnings details against capacity constraints and uncertainty around how durable royalty revenue will be.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly results beat expectations and management raised its outlook, but shares fell as traders focused on rising costs, weaker free cash flow, and a loss in the insurance business. Bulls view the selloff as an overreaction to a strong report, while bears point to cost and execution concerns and continued technical weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?

AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.

Jim Cramer Isn't Sure If There's Upside In This Health Care Stock

Cramer favors Howmet, remains cautious on AeroVironment, Rocket, AtaiBeckley and MP Materials, citing competition and limited upside.read more...

Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?

Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's  What You Should Know

The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance Raised

LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.

Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders?

Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?

LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower 

Equity

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%

The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>XBI has gained 25% this year and nearly 80% over the past 12 months, hitting its highest level since February 2021.</li><li>Biotech’s rebound is being driven by Big Pharma’s need to replace revenue threatened by looming patent expirations.</li><li>Vertex, AbbVie and GSK have each struck deals worth about $10 billion or more for late-stage or commercially ready assets.</li></ul>The AI and memory-chip rallies may have already minted their biggest winners, but biotech is mounting a breakout of its own, with the XBI biotech ETF sharply outperforming the broader market as cash-rich drugmakers race to buy promising pipelines before blockbuster patent losses begin eroding revenue.The&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> has gained 25% this year and nearly 80% over the past 12 months, eclipsing the broader market’s advance. The ETF hit its highest level since February 2021 on July 9, marking a turnaround from the prolonged biotech slump that followed the sector's pandemic-era boom.&nbsp;<img src="https://news.stocktwits-cdn.com/koyfin_20260723_125004124_png_a93a356a24.webp" alt="koyfin_20260723_125004124.png"><h2 class="st-heading-2">Big Pharma’s Patent Cliff Fuels Biotech M&amp;A</h2>The most powerful force behind the rebound is not simply improving investor sentiment, but it is Big Pharma’s urgent need for new drugs. Pharma companies have acquired 37 biotech businesses valued at $1 billion or more this year, already exceeding the previous annual record of 35, according&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/3778ec84-778f-4983-8ad9-85e7dbb5698d?syn-25a6b1a6=1">to</a> Stifel data cited by the Financial Times. Total biotech deal value has reached $216 billion, nearly doubling from $118 billion last year.The buying spree comes as several industry giants approach a steep patent cliff. Once exclusivity expires, cheaper generic or biosimilar competition can rapidly erode sales from blockbuster medicines.&nbsp;Morningstar&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.morningstar.com/business/insights/research/biopharma-landscape">estimates</a> that patent expirations could create a $139 billion revenue headwind for the largest biopharma companies through 2030. Keytruda, Merck’s top-selling cancer drug, and Bristol Myers Squibb’s Opdivo are among the major products facing patent pressure around 2028 and 2029. This leaves large drugmakers with two choices: develop replacements internally and accept years of clinical risk, or acquire companies whose drugs are already nearing approval or commercialization.<h2 class="st-heading-2">Big Pharma’s Buying Spree Tops $10B</h2>The buying spree has produced a string of multibillion-dollar deals targeting late-stage and commercially ready assets. Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, its largest-ever takeover, while AbbVie struck a $10.9 billion deal for Apogee Therapeutics' late-stage immunology pipeline. GSK paid $10.6 billion for Nuvalent to strengthen its oncology portfolio with two FDA-review lung cancer drugs.&nbsp;Eli Lilly, meanwhile, has emerged as the industry's most aggressive buyer, using obesity-drug windfalls to fund acquisitions across oncology, neuroscience and genetic medicines, most recently agreeing to acquire psychedelic drug developer AtaiBeckley for up to $3.8 billion.&nbsp;<h2 class="st-heading-2">Investors Hunt For Next Biotech Takeover</h2>With several high-profile targets already acquired, investors are looking for the next wave of biotech deals. Viking Therapeutics remains a leading candidate, with injectable and oral versions of obesity drug VK2735 offering buyers exposure to a GLP-1 market that Morningstar expects could approach $200 billion by 2035.Other potential targets include Structure Therapeutics, Revolution Medicines, Legend Biotech, Incyte, BioMarin, Ionis Pharmaceuticals and Moderna. Revolution Medicines offers a coveted RAS-targeted oncology pipeline, Legend provides commercial cell-therapy exposure through Carvykti, and Structure offers another route into oral obesity drugs. Syndax Pharmaceuticals and BioCryst Pharmaceuticals may also appeal to buyers seeking more de-risked commercial assets.Sellas Life Sciences (SLS) sits at the more speculative end of the watchlist. Its appeal hinges on the Phase 3 Regal trial of galinpepimut-S, or GPS, in AML. Sellas has recorded 78 of the 80 events needed to trigger the final analysis, putting it close to a pivotal readout. A positive survival outcome could boost its case as a late-stage oncology target. Its recent changes to executive change-of-control agreements have further fueled buyout speculation.<h2 class="st-heading-2">How Do Retail Traders Feel About XBI?</h2>On Stocktwits, retail sentiment toward XBI fell to a record-low score of 21 out of 100, shifting to ‘extremely bearish’ from ‘bearish’ a day earlier, amid ‘low’ message volume. The ticker’s watcher count has risen a modest 4% over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/xbi_ss_png_1dd85abfce.webp" alt="xbi ss.png" width="964" height="122"><figcaption>XBI sentiment and message volume as of July 23 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/JFDI/message/659748760">said</a>, “time for the $XBI to cool off and build out a handle.”<stembedurl>https://stocktwits.com/JFDI/message/659748760</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/The_Joker_has_Spoken/message/659692039">highlighted</a> an options open interest chart for XBI, suggesting that the heavy concentration of put open interest around the $150 strike could make it a key level to watch heading into the July 31 expiration.<stembedurl>https://stocktwits.com/The_Joker_has_Spoken/message/659692039</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-martin-shkreli-timing-aml-trial-data-wait-christmas/cZZnWveR7xB">SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas&nbsp;</a>

Biocryst Pharmaceuticals Inc.

Merck & Co Inc

SELLAS Life Sciences Group Inc

Viking Therapeutics Inc

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$ATAI my account shows my shares with .00001 average, but not showing any value? What happened here?

$ATAI what does it mean when my broker says i have recieved 2k CVRs due to a result of corporate action

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATAI AtaiBeckley Inc.

Fundamentals

Latest ATAI News